Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug titration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    213 result(s) found for: Drug titration. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-004224-59 Sponsor Protocol Number: MK-0431-848 Start Date*: 2016-07-27
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Met...
    Medical condition: Type 2 Diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-001788-21 Sponsor Protocol Number: RO-2455-302-RD Start Date*: 2014-04-11
    Sponsor Name:TAKEDA DEVELOPMENT CENTRE EUROPE LTD
    Full Title: A multicenter, randomized, double-blind phase 3 study to evaluate tolerability and pharmacokinetics of 500μg roflumilast once daily with an up-titration regimen in COPD, including an open-label do...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DE (Completed) HU (Completed) RO (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003077-15 Sponsor Protocol Number: EIG-LNF-002 Start Date*: 2015-11-23
    Sponsor Name:Eiger BioPharmaceuticals
    Full Title: A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of Titrating-Dose Lonafarnib in Combination with Ritonavir in Patients Chronically Infected w...
    Medical condition: Chronic Hepatitis D Virus (HDV) Infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003757-28 Sponsor Protocol Number: MEX-NM-301 Start Date*: 2020-06-24
    Sponsor Name:Lupin Europe GmbH
    Full Title: An Open-label, non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders
    Medical condition: Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2); ICD-10 code G71.1
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10028658 Myotonic disorders LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001835-33 Sponsor Protocol Number: CLCZ696B2228 Start Date*: 2013-09-19
    Sponsor Name:Novartis Pharma services AG
    Full Title: A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) SK (Completed) ES (Completed) DE (Completed) FI (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-004625-25 Sponsor Protocol Number: NN9068-4056 Start Date*: 2014-08-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) in subjects with type 2 diabetes mellitus using two different titration algorithms
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) AT (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000701-13 Sponsor Protocol Number: ISIS494372-CS3 Start Date*: 2014-08-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously t...
    Medical condition: High Lipoprotein(a)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10054009 Lipoprotein (a) increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001626-42 Sponsor Protocol Number: LPS14409 Start Date*: 2015-11-27
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabe...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) SK (Completed) DK (Completed) GR (Completed) SI (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000766-12 Sponsor Protocol Number: SCO/BIA-2093-301 Start Date*: 2005-03-21
    Sponsor Name:BIAL Portela & Companhia, S.A.
    Full Title: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial
    Medical condition: About 40% of the patients suffering from epilepsy are not satisfactorily controlled and 25% suffer from significant adverse events. This lack of seizure control means that combination therapy is of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004363-21 Sponsor Protocol Number: 1042-0603 Start Date*: 2015-03-11
    Sponsor Name:Marinus Pharmaceuticals, Inc
    Full Title: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Foll...
    Medical condition: Drug-Resistant Epilepsy with Partial-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000630-22 Sponsor Protocol Number: TV50717-CNS-30047 Start Date*: 2018-06-05
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a...
    Medical condition: Tics associated with Tourette Syndrome(TS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003286-21 Sponsor Protocol Number: SVUH-UCD-LEAD/CAR/01/2014 Start Date*: 2015-08-17
    Sponsor Name:University College Dublin
    Full Title: A multicentre, interventional, parallel group, randomised, open-label, exploratory study to assess the earlier introduction of Ivabradine in the Management of Systolic Dysfunction Heart Failure. Th...
    Medical condition: Heart Failure with reduced ejection fraction and borderline systolic blood pressure.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005515-16 Sponsor Protocol Number: 14-004 Start Date*: 2015-07-02
    Sponsor Name:Jazz Pharmaceuticals Inc.
    Full Title: A Six-Week, Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of ...
    Medical condition: Treatment of excessive sleepiness in adult patients with obstructive sleep apnea; to increase the ability to stay awake throughout the day.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003410-41 Sponsor Protocol Number: AOP18007 Start Date*: 2014-01-13
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE...
    Medical condition: male or female patients with confirmed diagnosis of Essential Thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007669-20 Sponsor Protocol Number: 37822681SCH2003 Start Date*: 2008-08-18
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000667-40 Sponsor Protocol Number: APD811-003 Start Date*: 2015-04-23
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PL (Completed) RO (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005057-31 Sponsor Protocol Number: APO-EPO-02 Start Date*: 2013-02-14
    Sponsor Name:APOTEX Inc.
    Full Title: A phase III, randomized, assessor-blinded, active-controlled, multicenter study of the efficacy and safety of APO-EPO as compared to Procrit® when given subcutaneously to patients with anemia of ch...
    Medical condition: Anemia and chronic kidney disease stage 5D (patients on stable hemodialysis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) BG (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003984-24 Sponsor Protocol Number: EPIsoDE_01 Start Date*: 2020-11-17
    Sponsor Name:Central Institute of Mental Health
    Full Title: A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression
    Medical condition: Treatment-Resistant Depressive Episode or Treatment-Resistant Recurrent Depressive Disorder of moderate to severe degree withoutpsychotic features
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002074-23 Sponsor Protocol Number: CAFQ056A2223 Start Date*: 2012-03-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in ...
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) IT (Completed) SK (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 21:49:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA